[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568469":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":31,"centralContacts":40,"locations":49,"responsibleParty":99,"collaborators":102,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":119,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":44,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":134,"overallStatus":143,"whyStopped":44,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"National Institute of Hygiene and Epidemiology, Vietnam","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 FSW","EXPERIMENTAL","100 FSWs aged 18-26 years receiving 3 doses of Gardasil-9 vaccine at 0-6-18 months",[13],"Biological: Human papillomavirus 9-valent vaccine, Recombinant",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 2 non-FSW","ACTIVE_COMPARATOR","100 non-FSW aged 18-26 years receiving 3 doses of Gardasil-9 vaccine at 0-6-18 months",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"Group 3 FSW","100 FSW aged 18-26 years receiving 3 doses of Gardasil-9 vaccine at 0-2-6 months",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"BIOLOGICAL","Human papillomavirus 9-valent vaccine, Recombinant","HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58",[9,15,20],[30],"Gardasil 9",[32,35,38],{"name":33,"affiliation":5,"role":34},"Hong T Duong, MD, PhD","STUDY_DIRECTOR",{"name":36,"affiliation":5,"role":37},"Trang V Nguyen, PhD","PRINCIPAL_INVESTIGATOR",{"name":39,"affiliation":5,"role":37},"Tuan A Le, MD, PhD",[41,46],{"name":36,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","84902028181",null,"nvt@nihe.org.vn",{"name":39,"role":42,"phone":47,"phoneExt":44,"email":48},"84983738688","lat@nihe.org.vn",[50,63,83],{"facility":51,"status":44,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":44},"Murdoch Children Research Institute","Parkville","Victoria","3052","Australia","AU",{"type":58,"coordinates":59},"Point",[60,61],144.95,-37.78333,{"lat":61,"lon":60},{"facility":64,"status":44,"city":65,"state":44,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Center for Supporting Community Development Initiatives SCDI-Vietnam","Haiphong","180000","Vietnam","VN",{"type":58,"coordinates":70},[71,72],106.68345,20.86481,{"lat":72,"lon":71},[75,79],{"name":76,"role":42,"phone":77,"phoneExt":44,"email":78},"Thanh TT Nham, MSc","84912069823","thamnham@scdi.org.vn",{"name":80,"role":42,"phone":81,"phoneExt":44,"email":82},"Nhung TH Tran, BSc","84326637935","nhungtran2@scdi.org.vn",{"facility":84,"status":44,"city":65,"state":44,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"Hai Phong Center for Disease Control",{"type":58,"coordinates":86},[71,72],{"lat":72,"lon":71},[89,93,97],{"name":90,"role":42,"phone":91,"phoneExt":44,"email":92},"Kien T Dong, MD, MSc","84987046688","dtk.skmt@gmail.com",{"name":94,"role":42,"phone":95,"phoneExt":44,"email":96},"Hai H Phan, MD, MPH","84903265275","hai.cdc.haiphong@gmail.com",{"name":90,"role":98,"phone":44,"phoneExt":44,"email":44},"SUB_INVESTIGATOR",{"type":37,"investigatorFullName":100,"investigatorTitle":101,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Nguyen Van Trang","Acting Manager, Center for Biomedical Researches",[103,105,108],{"name":104,"class":6},"Murdoch Childrens Research Institute",{"name":106,"class":107},"CENTER FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES","UNKNOWN",{"name":84,"class":109},"OTHER_GOV","100568469","phase-2-effector-and-memory-immune-responses-to-hpv-vaccination-in-vietnamese-women-post-virus-exposure-100568469",false,"NCT06681636","Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure","A Non-inferiority Study Comparing the Immunogenicity of a Standard or an Extended Three-dose Nonavalent Human Papillomavirus Vaccine Schedule Between High-risk Women Aged 18-26 Years and Age-matched Women in the General Population","HPV9vxFSW","Inclusion Criteria:\n\n* Is between the reporting ages of 18-26 years at the time of recruitment.\n* Engage in commercial sex in the last 6m (for FSW group) or have engaged in sexual activity (non-FSWs)\n* Willing and able to give written informed consent.\n* Willing to complete the follow-up requirements of the study.\n\nExclusion criteria\n\nParticipants meeting any of the following criteria will be excluded from the trial:\n\n* Pregnant or possibly pregnant\n* Has received any HPV vaccine previously\n* Has an axillary temperate greater than 38°C\n* Known allergies to any vaccine component\n* incapacity to provide consent\n* Currently receiving immunosuppressive medication or anti-cancer chemotherapy.\n* Known HIV infection.\n* Known Congenital immune deficiency syndrome.",true,"FEMALE","18 Years","26 Years",{"count":123,"type":124},300,"ESTIMATED","INTERVENTIONAL",[127],"PHASE2","A Study to evaluate if the 3 dose extended schedule (0-6-18 months) for the HPV vaccine Gardasil-9 provide similar immune responses and short term protection against HPV infection compared to the regular 3 dose schedule (0-2-6 months) in high risk women in Vietnam",[130,131,132,133],"HPV Infection","Cervical Cancer","Anogenital Cancer","Anogenital Warts",[135,136,67,137,138,139,140,141,142],"human papillomavirus","HPV vaccine","Female sex workers","immunogenicity","protection","extended schedule","HPV infection","cervical cancer","NOT_YET_RECRUITING","2024-11-07",{"date":146,"type":147},"2024-11-08","ACTUAL",{"date":149,"type":124},"2024-12-14",{"date":151,"type":124},"2027-12-31",{"name":5,"class":6},3]